A Series B financing round has raised Genesis Therapeutics’ total capital to over $280 million, which will be used to bring the company’s artificial intelligence (AI)-enabled pipeline into clinical development.
Genesis will also invest in continued development of generative and predictive AI methods, which form the foundation of the Genesis Exploration of Molecular Space (GEMS) platform.
“AI presents a potent opportunity to revolutionise the drug discovery process, which frequently struggles to produce viable drug candidates against targets that are biologically well-validated but considered undruggable due to highly challenging chemistry,” said CEO Evan Feinberg.
“This funding comes as Genesis is approaching an inflection point with the first of our AI-enabled drug candidates entering the clinic. The addition of our new lead investor, and other meaningful additions to our biotech and AI-oriented syndicate, will support Genesis in developing breakthrough therapies for patients with severe unmet medical needs, and their families, capitalising on the broad applicability and potential of the GEMS AI platform.”
Genesis’ internal pipeline programmes use the GEMS AI platform, which leverages generative and predictive AI methods to produce novel molecules and make rapid, accurate predictions of properties such as potency, selectivity, and ADMET.
Edited by Diana Spencer, Senior Digital Content Editor, Drug Discovery World
